Sensitivity and specificity of the Prostate Health Index (PHI) for prostate cancer screening, avoiding unnecessary biopsies
DOI:
https://doi.org/10.48193/y3k71796Keywords:
Prostate cancerAbstract
No en carta al editor
References
Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, et al. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. The International Journal of Biological Markers. 2009;24(2): 65–69. https://doi.org/10.5301/jbm.2009.1349.
Garrido MM, Marta JC, Ribeiro RM, Pinheiro LC, Holdenrieder S, Guimarães JT. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations. In Vivo (Athens, Greece). 2021;35(6): 3431–3439. https://doi.org/10.21873/invivo.12643.
Deng L, Yue D, Wang X, Li H. Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen. Translational Andrology and Urology. 2023;12(2): 261–270. https://doi.org/10.21037/tau-23-29.
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. The Journal of Urology. 2023;210(1): 46–53. https://doi.org/10.1097/JU.0000000000003491.
Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine. 2022;60(8): 1261–1277. https://doi.org/10.1515/cclm-2022-0354.
Coronel-Carvajal C. Los objetivos de la investigación. Revista Archivo Médico de Camagüey. 2023;27.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista Mexicana de Urología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
